Results 231 to 240 of about 1,032,826 (402)

Clinical Phenotype and Neuroimaging Findings in Siblings with COX15 Deficiency: Case Report and Review of Previously Reported Cases

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Haya S. AlFaris   +8 more
wiley   +1 more source

A Multimarker Model for Prostate Cancer Risk Assessment: Improving Diagnostic Accuracy Beyond PSA

open access: yesThe Prostate, EarlyView.
ABSTRACT Objective This study aimed to evaluate the association between biochemical markers and prostate cancer (PCa) risk by analyzing patients with benign prostatic hyperplasia (BPH) and PCa. Additionally, the study sought to assess the diagnostic accuracy of a multimarker model compared to prostate‐specific antigen (PSA) alone.
Penglu Yang, Bin Yang
wiley   +1 more source

Deep Brain Stimulation in a Child with Aicardi‐Goutières Syndrome‐7 (AGS7): A Case Report and Literature Review

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Sangeetha Yoganathan   +10 more
wiley   +1 more source

Single and dual RPA‐CRISPR/Cas assays for point‐of‐need detection of Stewart's wilt pathogen (Pantoea stewartii subsp. stewartii) of corn and Maize dwarf mosaic virus

open access: yesPest Management Science, Volume 81, Issue 4, Page 1988-1999, April 2025.
Schematic diagram of the single and dual RPA‐CRISPR/Cas12a/13a diagnostic assays for the detection of Pantoea stewartii subsp. stewartii and Maize dwarf mosaic virus. The validated assays provide a useful and sensitive molecular tool for detecting two quarantine pathogens of maize within a minimal resource framework suitable for fast‐tracking the ...
Qian Tian   +6 more
wiley   +1 more source

Clinical modeling of motor function to predict treatment efficacy and enable in silico treatment comparisons in infantile‐onset Pompe disease

open access: yesCPT: Pharmacometrics &Systems Pharmacology, EarlyView.
Abstract Infantile‐onset Pompe disease (IOPD) is a rare, deadly, quickly‐progressing degenerative disease. Even with life‐sustaining treatment (e.g., alglucosidase alfa [ALGLU]), many patients experience continued motor impairment. The Mini‐COMET trial evaluated avalglucosidase alfa (AVAL) versus ALGLU on motor and other outcomes in IOPD.
Fatiha Rachedi   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy